CBL-514
Early humanInvestigational small molecule agent
Research material. Not for human or animal consumption.
Research overview
CBL-514 is an investigational injectable small molecule, not a peptide, developed by Caliway Biopharmaceuticals in Taiwan. It is designed to reduce localised subcutaneous fat by triggering apoptosis of fat cells at the injection site, aiming to avoid the inflammation and tissue damage of agents that dissolve cell membranes. A peer-reviewed Phase IIa study reported reductions in ultrasound-measured abdominal fat, and further studies cover cellulite. It is not authorised as a medicine.
Limited, exploratory, early phase or small human studies have been identified.
Questions about CBL-514
PRODUCT QUESTIONSWhat is CBL-514?
CBL‑514 is an investigational small molecule agent studied for localized subcutaneous fat reduction and related aesthetic indications in early human research.
What research has been published on CBL-514?
CBL-514 is an investigational small molecule given by subcutaneous injection for localised fat. Peer reviewed Phase IIa work reported reductions in ultrasound measured abdominal subcutaneous fat, while registered Phase II studies have examined cellulite. Dercum disease and lipoma programmes remain exploratory. CBL-514 is not an authorised medicine, and early findings do not establish long term safety or approved efficacy.
What batch documentation should accompany CBL-514?
CBL-514: Ask for the COA and analytical reports for the batch being quoted. As a small molecule, identity should be confirmed by NMR and mass spectrometry, with HPLC purity and residual solvent data.
How should CBL-514 storage conditions be assessed?
CBL-514: Storage depends on the supplied form. Keep the dry solid sealed and protected from light at the temperature stated in the batch documentation, and test solution stability before storing prepared formulations.